Allucent Granted COVID-19 Booster Vaccine Contract

Image Credit: Adobe Stock Images/Ralf

Allucent, a clinical research organization (CRO), has officially been chosen to fast-track clinical research and development for new COVID-19 vaccine candidates by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. As part of the contract, Allucent will hold a 10,000-participant Phase IIb clinical trial designed to measure efficacy of next-generation vaccine candidates compared to authorized treatments to prevent symptomatic, PCR-confirmed SARS-CoV-2 infection.

"Allucent is honored to have been chosen by BARDA for this critical initiative," said Mark A. Goldberg, MD, chairman, CEO, Allucent, in a company press release. "This collaboration represents a significant step forward in our collective efforts to combat COVID-19 and its variants. We are excited to leverage our expertise and resources to help develop next-generation booster vaccines that will enhance global immunity and save lives. This award results from our focused investment in countering infectious diseases and further builds upon our growing federally funded clinical trials portfolio."

Reference: Allucent Awarded BARDA Contract to Support Acceleration of Next-Generation COVID-19 Booster Vaccines. PR Newswire. August 28, 2023. Accessed August 29, 2023. https://www.prnewswire.com/news-releases/allucent-awarded-barda-contract-to-support-acceleration-of-next-generation-covid-19-booster-vaccines-301910678.html